Biological therapy in the treatment of psoriatic arthritis: economic and epidemiological considerations

References

• Guerra Junior AA, Pereira RG, Andrade EIG, et al. Building the national database of health centred on the individual: administrative and epidemiological record linkage - Brazil, 2000–2015. Int J Popul Data Sci. 2018;3(1):20. doi:10.23889/ijpds.v3i1.446.
   Google Scholar
• Brasil. Ministério da Saúde. Gabinete do Ministro. Portaria nº 2981 de 26 de novembro de 2009. Aprova o Componente Especializado da Assistência Farmacêutica. 2009. Anexo IV. [cited 2018 sep 19]. Available from: http://bvsms.saude.gov.br/bvs/saudelegis/gm/2009/prt2981_26_11_2009_rep.html
   Google Scholar
• Brasil. Presidência da República. Casa Civil. Lei n 12.401, de 28 de abril de 2011. Altera a Lei no 8.080, de 19 de setembro de 1990, para dispor sobre a assistência terapêutica e a incorporação de tecnologia em saúde no âmbito do Sistema Único de Saúde - SUS. [cited 2018 sep 19]. Available from: http://www.planalto.gov.br/ccivil_03/_Ato2011-2014/2011/Lei/L12401.htm
   Google Scholar
• Brasil. Presidência da República. Casa civil. Emenda constitucional n 95, de 15 de dezembro de 2016. Altera o Ato das Disposições Constitucionais Transitórias, para instituir o Novo Regime Fiscal, e dá outras providências. [cited 2018 sep 19]. Available from: www.planalto.gov.br/ccivil_03/constituicao/emendas/emc/emc95.htm
   Google Scholar
• Brasil. Ministério da Saúde. Secretaria de Ciência, Tecnologia e Insumos Estratégicos. Departamento de Gestão e Incorporação de Tecnologias em Saúde. Comissão Nacional de Incorporação de Tecnologias no SUS – CONITEC. Diretrizes Metodológicas avaliação de desempenho de tecnologias em saúde - Desinvestimento e Reinvestimento. Ministério da Saúde. p. 23. 2016. [cited 2018 sep 19]. Available from: http://conitec.gov.br/images/Consultas/2016/diretrizf_investimento_reinvestimento.pdf
   Google Scholar
• D’Angiolella LS, Cortesi PA, Lafranconi A, et al. Cost and cost effectiveness of treatments for psoriatic arthritis: a systematic literature review. Pharmacoeconomics. 2018 May; 36(5):567–589. DOI:10.1007/s40273-018-0618-5.
   PubMed Web of Science ®Google Scholar
• Warren RB, Smith CH, Yiu ZZN, et al. Differential drug survival of biologic therapies for the treatment of psoriasis: a prospective observational cohort study from the British Association Of Dermatologists Biologic Interventions Register (BADBIR). J Invest Dermatol. 2015 Nov;135(11):2632–2640. DOI:10.1038/jid.2015.208.
   PubMed Web of Science ®Google Scholar
• Carrascosa JM, van Doorn MB, Lahfa M, et al. Clinical relevance of immunogenicity of biologics in psoriasis: implications for treatment strategies. J Eur Acad Dermatol Venereol. 2014 Nov;28(11):1424–1430. DOI:10.1111/jdv.12549.
   PubMed Web of Science ®Google Scholar
• Neovius M, Arkema EV, Olsson H, et al. ARTIS study group. Drug survival on TNF inhibitors in patients with rheumatoid arthritis comparison of adalimumab, etanercept and infliximab. Ann Rheum Dis. 2015 Feb;74(2):354–360. DOI:10.1136/annrheumdis-2013-204128.
   PubMed Web of Science ®Google Scholar
• Aaltonen K, Heinonen A, Joensuu J, et al. Effectiveness and drug survival of TNF-inhibitors in the treatment of psoriatic arthritis: A prospective cohort study. Semin Arthritis Rheum. 2017 Jun;46(6):732–739. DOI:10.1016/j.semarthrit.2016.09.005.
   PubMed Web of Science ®Google Scholar
• Stober C, Ye W, Guruparan T, et al. Prevalence and predictors of tumour necrosis factor inhibitor persistence in psoriatic arthritis. Rheumatology (Oxford). 2018 Jan 1;57(1):158–163. DOI:10.1093/rheumatology/kex387.
   PubMed Web of Science ®Google Scholar
• Soubrier AS, Bele-Philippe P, Cortet B, et al. Treatment response, drug survival and safety of anti-tumour necrosis factor α therapy in 193 patients with psoriatic arthritis: a twelve-year “real life” experience. Joint Bone Spine. 2015 Jan;82(1):31–37. DOI:10.1016/j.jbspin.2014.08.001.
   PubMed Web of Science ®Google Scholar
• Glintborg B, Østergaard M, Dreyer L, et al. Treatment response, drug survival, and predictors thereof in 764 patients with psoriatic arthritis treated with anti-tumor necrosis factor α therapy: results from the nationwide Danish DANBIO registry. Arthritis Rheum. 2011 Feb;63(2):382–390. DOI:10.1002/art.30117.
   PubMed Web of Science ®Google Scholar
• Iannone F, Lopriore S, Bucci R, et al. Two-year survival rates of anti-TNF-α therapy in psoriatic arthritis (PsA) patients with either polyarticular or oligoarticular PsA. Scand J Rheumatol. 2015 May;44(3):192–199. DOI:10.3109/03009742.2014.962081.
   PubMed Web of Science ®Google Scholar
• Anghel LA, Farcaş AM, Oprean RN. Medication adherence and persistence in patients with autoimmune rheumatic diseases: a narrative review. PatientPreferAdherence. 2018 Jul 3;12: 1151–1166. DOI:10.2147/PPA.S165101.
   Google Scholar
• World Bank, International Comparison Program database. 2018. [cited 2018 sep 19]. Available in: https://data.worldbank.org/indicator/PA.NUS.PPP?end=2015&locations=BR&start=2010
   Google Scholar
• Garrido MM, Kelley AS, Paris J, et al. Methods for constructing and assessing propensity scores. Health Serv Res. 2014 Oct;49(5):1701–1720. DOI:10.1111/1475-6773.12182.
   PubMed Web of Science ®Google Scholar
• Quan H, Sundararajan V, Halfon P, et al. Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data. Med Care. 2005 Nov;43(11):1130–1139.
   PubMed Web of Science ®Google Scholar
• Pogácsás L, Borsi A, Takács P, et al. Long-term drug survival and predictor analysis of the whole psoriatic patient population on biological therapy in Hungary. J Dermatolog Treat. 2017 Nov;28(7):635–641. DOI:10.1080/09546634.2017.1329504.
   PubMed Web of Science ®Google Scholar
• Flouri ID, Markatseli TE, Boki KA, et al. Comparative analysis and predictors of 10-year tumor necrosis factor inhibitors drug survival in patients with spondyloarthritis: first-year response predicts longterm drug persistence. J Rheumatol. 2018 Jun;45(6):785–794. DOI:10.3899/jrheum.170477.
   PubMed Web of Science ®Google Scholar
• Fagerli KM, Kearsley-Fleet L, Watson KD, et al. Long-term persistence of TNF-inhibitor treatment in patients with psoriatic arthritis. Data from the British society for rheumatology biologics register. RMD Open. 2018 Jan 7;4(1):e000596. DOI:10.1136/rmdopen-2017-000596.
   PubMed Web of Science ®Google Scholar
• Silva CR, Carvalho BG, Júnior CL, et al. Difficulties in accessing services that are of medium complexity in small municipalities: a case study. Cien Saude Colet. 2017 Apr;22(4):1109–1120. DOI:10.1590/1413-81232017224.27002016.
   PubMed Web of Science ®Google Scholar
• Albuquerque CP, Santos-Neto LLD. Development of rheumatology training in Brazil: the option for a medical residency program. Rev Bras Reumatol. 2017;57(6):507–513. São Paulo. doi:10.1016/j.rbre.2016.04.001.
   Google Scholar
• Silva MRR, Dos Santos JBR, Almeida AM, et al. 925 supply of drugs for the treatment of psoriatic arthritis in the Brazilian public health system. Pharmacoepidemiol Drug Saf. 2018;27:3–521. Page 424. In: Abstract. DOI:10.1002/pds.4629.
   Web of Science ®Google Scholar
• Travassos C, Oliveira EXG, Viacava F. Desigualdades geográficas e sociais no acesso aos serviços de saúde no Brasil: 1998 e 2003. Ciênc Saúde Coletiva. 2006;11(4):975–986.
   Google Scholar
• Macinko J, Lima-Costa MF. Horizontal equity in health care utilization in Brazil, 1998–2008. Int J Equity Health. 2012 Jun 21;11:33. DOI:10.1186/1475-9276-11-33. Erratum in: Int J Equity Health. 2014;13:101.
   PubMed Web of Science ®Google Scholar
• Albuquerque MV, Viana ALD, Lima LD, et al. Regional health inequalities: changes observed in Brazil from 2000–2016. Cien Saude Colet. 2017 Apr;22(4):1055–1064. DOI:10.1590/1413-81232017224.26862016.
   PubMed Web of Science ®Google Scholar
• Da Silva MRR, Dos Santos JBR, Almeida AM, et al. Effectiveness and safety of anti-TNF in psoriatic arthritis patients in Brazil: a post-incorporation analysis. J Comp Eff Res. 2018. DOI:10.2217/cer-2018-0017.
   PubMed Web of Science ®Google Scholar
• Favalli EG, Selmi C, Becciolini A, et al. Eight-year retention rate of first-line tumor necrosis factor inhibitors in spondyloarthritis: a multicenter retrospective analysis. Arthritis Care Res (Hoboken). 2017 Jun;69(6):867–874. DOI:10.1002/acr.23090.
   PubMed Web of Science ®Google Scholar
• Ribeiro Da Silva MR, Ribeiro Dos Santos JB, Maciel AA, et al. Medication persistence for psoriatic arthritis in a Brazilian real-world setting. Future Sci OA. 2019 Jan 18;5(2):FSO369. DOI:10.4155/fsoa-2018-0101.
   PubMed Web of Science ®Google Scholar
• Saad AA, Ashcroft DM, Watson KD, et al. Efficacy and safety of anti-TNF-α therapies in psoriatic arthritis: an observational study from the British society for rheumatology biologics register. Rheumatology (Oxford). 2010;49(4):697–705.
   PubMed Web of Science ®Google Scholar
• Malaviya AP, Ostör AJ. Drug adherence to biologic DMARDS with a special emphasis on the benefits of subcutaneous abatacept. Patient Prefer Adherence. 2012;6:589–596.
   PubMed Web of Science ®Google Scholar
• Dos Santos JBR, Guerra Junior AA, da Silva MRR, et al. First line of biological drugs in rheumatoid arthritis: a medication persistence analysis. Expert Rev Clin Pharmacol. 2019 Apr;12(4):363-370. DOI:10.1080/17512433.2019.1586533.
   Google Scholar
• Cortesi PA, Scalone L, D’Angiolella L, et al. Systematic literature review on economic implications and pharmacoeconomic issues of psoriatic arthritis. Clin Exp Rheumatol. 2012 Jul - Aug; 30:(4 Suppl 73):S126–31.
   PubMed Web of Science ®Google Scholar
• Schabert VF, Watson C, Gandra SR, et al. Annual costs of tumor necrosis factor inhibitors using real-world data in a commercially insured population in the United States. J Med Econ. 2012;15(2):264–275.
   PubMedGoogle Scholar
• Cawson MR, Mitchell SA, Knight C, et al. Systematic review, network meta-analysis and economic evaluation of biological therapy for the management of active psoriatic arthritis. BMC Musculoskelet Disord. 2014;15:26. DOI:10.1186/1471-2474-15-26.
   PubMed Web of Science ®Google Scholar
• Gu T, Shah N, Deshpande G, et al. Comparing biologic cost per treated patient across indications among adult US managed care patients: a retrospective cohort study. Drugs Real World Outcomes. 2016 Dec;3(4):369–381.
   PubMedGoogle Scholar
• Bonafede MM, Gandra SR, Watson C, et al. Cost per treated patient for etanercept, adalimumab, and infliximab across adult indications: a claims analysis. Adv Ther. 2012 Mar;29(3):234–248. DOI:10.1007/s12325-012-0007-y.
   PubMed Web of Science ®Google Scholar
• Yang TS, Chi CC, Wang SH, et al. Cost-efficacy of biologic therapies for psoriatic arthritis from the perspective of the Taiwanese healthcare system. Int J Rheum Dis. 2016 Oct;19(10):1002–1009. DOI:10.1111/1756-185X.12744.
   PubMed Web of Science ®Google Scholar
• Gulácsi L, Brodszky V, Baji P, et al. Biosimilars for the management of rheumatoid arthritis: economic considerations. Expert Rev Clin Immunol. 2015;11(Suppl 1):S43–52.
   PubMed Web of Science ®Google Scholar
• Aladul MI, Fitzpatrick RW, Chapman SR. The effect of new biosimilars in rheumatology and gastroenterology specialities on UK healthcare budgets: results of a budget impact analysis. Res Social Adm Pharm. 2019 Mar; 15(3):310–317. DOI:10.1016/j.sapharm.2018.05.009.
   PubMed Web of Science ®Google Scholar
• Brazil. National Health Surveillance Agency (ANVISA). Medication Market Regulation Chamber (CMED). Drug price list. Maximum Sale Price to the Government. [updated 2019 May 21; cited 2019 May 28]. Available from: http://portal.anvisa.gov.br/documents/374947/2829072/xls_conformidade_gov_site_2019_05_21.xls/cbdb8eed-34a4-4213-a569-386bcc45f016
   Google Scholar
• Scheinberg MA, Felix PAO, Kos IA, et al. Partnership for productive development of biosimilar products: perspectives of access to biological products in the Brazilian market. Einstein (Sao Paulo). 2018 Sep 17;16(3):eRW4175. DOI:10.1590/S1679-45082018RW4175.
   PubMed Web of Science ®Google Scholar
• Geurts MM, Talsma J, Brouwers JR, et al. Medication review and reconciliation with cooperation between pharmacist and general practitioner and the benefit for the patient: a systematic review. Br J Clin Pharmacol. 2012 Jul;74(1):16–33. DOI:10.1111/j.1365-2125.2012.04178.x.
   PubMed Web of Science ®Google Scholar
• Marra CA, Grubisic M, Cibere J, et al. Cost-utility analysis of a multidisciplinary strategy to manage osteoarthritis of the knee: economic evaluation of a cluster randomized controlled trial study. Arthritis Care Res (Hoboken). 2014 Jun;66(6):810–816. DOI:10.1002/acr.22232.
   PubMed Web of Science ®Google Scholar
• O’Dwyer JL, Meads DM, Hulme CT, et al. The cost-effectiveness of tight control of inflammation in early psoriatic arthritis: economic analysis of the TICOPA trial. Arthritis Care Res (Hoboken). 2017 May 23. DOI:10.1002/acr.23293.
   Google Scholar
• Gossec L, McGonagle D, Korotaeva T, et al. Minimal disease activity as a treatment target in psoriatic arthritis: a review of the literature. J Rheumatol. 2017 Nov 15;170449. DOI:10.3899/jrheum.170449.
   Google Scholar